JP5458368B2 - Manufacturing method of onychomycosis model - Google Patents

Manufacturing method of onychomycosis model Download PDF

Info

Publication number
JP5458368B2
JP5458368B2 JP2008321700A JP2008321700A JP5458368B2 JP 5458368 B2 JP5458368 B2 JP 5458368B2 JP 2008321700 A JP2008321700 A JP 2008321700A JP 2008321700 A JP2008321700 A JP 2008321700A JP 5458368 B2 JP5458368 B2 JP 5458368B2
Authority
JP
Japan
Prior art keywords
nail
model
onychomycosis
fungus
humidity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2008321700A
Other languages
Japanese (ja)
Other versions
JP2010142149A (en
Inventor
信雄 久保田
沙織 長坂
通子 小澤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pola Pharma Inc
Original Assignee
Pola Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pola Pharma Inc filed Critical Pola Pharma Inc
Priority to JP2008321700A priority Critical patent/JP5458368B2/en
Publication of JP2010142149A publication Critical patent/JP2010142149A/en
Application granted granted Critical
Publication of JP5458368B2 publication Critical patent/JP5458368B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Description

本発明は、爪白癬のための抗真菌剤の評価などに有用な爪白癬モデルに関し、更に詳細には、生体から離れた形で製造され、in vitro爪白癬モデルに関する。   The present invention relates to an onychomycosis model useful for evaluating an antifungal agent for onychomycosis, and more particularly to an in vitro onychomycosis model manufactured away from a living body.

社会の高齢化に伴い、これまでには問題とされなかった疾病が大きな問題となってきている。その一つに高脂血症、高血圧、糖尿病などの複合化された代謝疾患症候群が存するが、これらの広がりに伴い、真菌感染症も重大な疾患に変貌しつつある。即ち、糖尿病などにおいては、創傷治癒性が著しく減じるために、体部白癬、足部白癬或いは爪白癬などの真菌症が、広汎な体部組織の破壊を誘起してしまう現象が知られている。この為、これらの真菌症を完治させることが、代謝疾患症候群の治療には重要なポイントとなっている。これらの真菌症の内、爪白癬は、薬剤の治療効果が低く、且つ、爪白癬に保持された真菌が皮膚の真菌症の再発に繋がることが存するために、特に重大な疾患であると言える。この為、この様な爪白癬の治療剤の開発が望まれているが、開発された薬剤が爪白癬に有効であるか否かは、臨床試験が終わらなければ判らない状況にあった。即ち、適切な爪白癬治療効果の評価モデルが存しなかったと言える。これも爪白癬モデル自信が存しないことに起因する。   With the aging of society, diseases that have not been considered as problems have become a major problem. One of them is a complex metabolic disease syndrome such as hyperlipidemia, hypertension, and diabetes. With the spread of these syndromes, fungal infections are becoming a serious disease. That is, in diabetes and the like, wound healing properties are significantly reduced, so that a phenomenon in which mycosis such as body ringworm, foot ringworm or onychomycosis induces destruction of extensive body tissues is known. . Therefore, it is an important point for the treatment of metabolic disease syndrome to completely cure these mycoses. Among these mycoses, onychomycosis is a particularly serious disease because the therapeutic effect of the drug is low and the fungi retained in onychomycosis can lead to the recurrence of cutaneous mycosis. . For this reason, development of such a therapeutic agent for onychomycosis is desired. However, whether or not the developed drug is effective for onychomycosis has been unclear until clinical trials are completed. That is, it can be said that there was no appropriate evaluation model for the treatment effect of onychomycosis. This is also due to the lack of confidence in the onychomycosis model.

爪白癬症に対する抗真菌剤の効果を評価する動物モデルとして、動物に真菌を感染させる方法はいくつか報告されているものの(非特許文献1から非特許文献3)、感染までの期間が長く、再現性よく感染モデルが作製出来るといった点では十分ではなかった。これは爪の構造と、白癬菌の宿主、寄生場所の選択特性によるものであると考えられていた。また、爪真菌症については前述のようにいくつかの課題があり、評価期間や再現性の問題があるにもかかわらず、課題を解決するための動物感染モデルの検討はほとんど行われていない。感染モデルの作製方法として、免疫力を低下させ、感染しやすい状態にさせることは報告されている(非特許文献4)。培地上にOリングを介して爪を配置し、Oリングと爪との間に真菌の分生子分散液を存在させて作成するin vitro感染爪モデルは存する(例えば、特許文献1を参照)が、偶発的要素によって左右されやすい、真菌と爪との接触状態に感染が依存することから、その再現性には検討の余地が存した。言い換えれば、再現性の高い生体から離れたin vitro爪感染モデルは得られておらず、再現性の高い検討は保証されていないのが現状であった。   As an animal model for evaluating the effect of antifungal agents against onychomycosis, although several methods for infecting animals with fungi have been reported (Non-patent Document 1 to Non-patent Document 3), the period until infection is long, It was not enough in that an infection model could be made with good reproducibility. This was thought to be due to the nail structure and the host trait of the tinea fungus, the selective nature of the parasitic location. In addition, there are several problems with onychomycosis as described above, and despite the problems of evaluation period and reproducibility, studies on animal infection models for solving the problems have hardly been conducted. As a method for preparing an infection model, it has been reported that the immunity is reduced to make it susceptible to infection (Non-patent Document 4). There is an in vitro infected nail model in which a nail is placed on a medium via an O-ring and a fungal conidial dispersion is present between the O-ring and the nail (see, for example, Patent Document 1). Because the infection depends on the state of contact between the fungus and the nail, which is easily influenced by accidental factors, the reproducibility has left room for examination. In other words, an in vitro nail infection model away from a living body with high reproducibility has not been obtained, and examination with high reproducibility has not been guaranteed.

一方、爪真菌感染系と温湿度との間には何らかの因果関係が存在することが予測されるが、その因果関係が如何様なものかはつまびらかにはされたいないのが現状である。   On the other hand, it is predicted that some kind of causal relationship exists between the nail fungus infection system and temperature and humidity, but the current situation is that it has not been clarified what the causal relationship is.

Antimicrobial agents and chemotherapy, 46(12), p.3797-3801 (2002)Antimicrobial agents and chemotherapy, 46 (12), p.3797-3801 (2002) Microbiol.Immunol.,47(2),p143-146 (2003)Microbiol.Immunol., 47 (2), p143-146 (2003) Mycoses, 48, p108-113 (2004)Mycoses, 48, p108-113 (2004) Jpn. J. Infect Dis., 60, p.33-39 (2007)Jpn. J. Infect Dis., 60, p.33-39 (2007) 特開2001−133449 号公報JP 2001-133449 A

本発明は、この様な状況下為されたものであり、再現性の高い生体から離れたin vitro爪白癬モデルを提供することを課題とする。   The present invention has been made under such circumstances, and an object thereof is to provide an in vitro onychomycosis model away from a living body with high reproducibility.

この様な実情に鑑みて、本発明者らは、再現性の高い生体から離れたin vitro爪白癬モデルを求めて、鋭意研究努力を重ねた結果、ヒトを含む動物より採取した非感染爪の爪床側に、予め培養して定量可能な状態に調整した、真菌乃至は分生子の分散液を播種し、水性担体と接することなく、低温高湿条件で長期間培養することにより、再現性良く爪白癬がin vitroで作成できることを見出し、発明を完成させるに至った。即ち、本発明は、以下に示す通りである。
(1)爪全体が均一な深度で感染した爪白癬モデルであって、ヒトを含む動物より採取した非感染爪の爪床側に、予め培養して定量可能な状態に調整した、真菌乃至は分生子の分散液を播種し、水性担体と接することな く、温度25〜30℃、湿度90〜100%の範囲にて、7〜14日間、且つ、爪甲側よりも爪床側の湿度が高い状態で培養することを特徴とする、爪白癬モデルの製造法。
(2)(1)に記載の爪白癬モデルの製造方法で製造されたモデルの爪甲側に抗真菌剤を投与し、爪中の真菌の状態をATP産生量を指標に、ATP産生量が大きいときには、生存真菌の量が多く、ATP産生量が低いときには、生存真菌の量が少ないと判別し、投与により生存菌数が減じる程度が高い薬剤ほど抗真菌効果の高い薬剤であると鑑別することを特徴とする、抗真菌薬剤の効果の鑑別法。
(3)(1)に記載の爪白癬モデルの製造方法において、温度25〜30℃、湿度90〜100%の範囲にて、7〜14日間、且つ、爪甲側よりも爪床側の湿度を高く保つための治具であって、爪の水分非透過性に依存し密閉すべき構造を構築する、爪よりも小さい窓部を有する2枚のアタッチメントとアタッチメントと爪で密閉されるべき空間を有する、水性担体保持可能なチャンバーとを構成要件とする爪白癬モデル作成用の治具。
(4)前記治具は、爪とアタッチメントとの接触部の間に弾性緩衝体を有することを特徴とする、(1)記載の治具。
In view of such circumstances, the present inventors have sought for an in vitro nail ringworm model away from a highly reproducible living body, and as a result of earnest research efforts, the present inventors have obtained uninfected nail samples collected from animals including humans. Reproducibility by inoculating the nail bed side with a fungal or conidial dispersion that has been cultivated in advance and adjusted to a quantifiable state, and cultivating it for a long time under low-temperature and high-humidity conditions without contact with an aqueous carrier. It was found that onychomycosis can be made in vitro, and completed the invention. That is, the present invention is as follows.
(1) A nail ringworm model in which the entire nail is infected at a uniform depth, wherein the fungus or habitat is cultivated and quantified in advance on the nail bed side of a non-infected nail collected from an animal including a human. seeded conidia dispersion, such that contact with the aqueous carrier Ku, temperature 25 to 30 ° C., at a humidity of 90% to 100% range, 7-14 days, and the humidity of the nail bed side from the nail plate side A method for producing an onychomycosis model, characterized by culturing in a high state.
(2) An antifungal agent is administered to the nail plate side of the model produced by the method for producing an onychomycosis model as described in (1), and the ATP production amount is measured using the ATP production amount as an indicator of the state of the fungus in the nail. When the amount is large, the amount of viable fungi is large, and when the amount of ATP produced is low, it is determined that the amount of viable fungus is small, and a drug whose degree of viable bacteria is reduced by administration is identified as a drug having a higher antifungal effect. A method for differentiating the effect of an antifungal drug, characterized in that
(3) In the method for producing an onychomycosis model as described in (1), the temperature is 25 to 30 ° C., the humidity is 90 to 100%, and the humidity is on the nail bed side rather than the nail plate side for 7 to 14 days. Is a jig to keep the height high, and builds a structure to be sealed depending on the moisture impermeability of the nail, and has two attachments with a window smaller than the nail, and a space to be sealed with the nail A jig for creating a model for onychomycosis comprising a chamber capable of holding an aqueous carrier.
(4) The jig according to (1), wherein the jig includes an elastic buffer between contact portions of the claw and the attachment.

本発明によれば、再現性の高い生体から離れたin vitro爪白癬モデルを提供することができる。   According to the present invention, it is possible to provide an in vitro onychomycosis model away from a living body with high reproducibility.

本発明の爪白癬モデルは、ヒトを含む動物より採取された、真菌に感染されていない爪を用いて、これに爪を栄養源とする真菌を繁殖させ、in vitroで爪白癬の状態を作り出すことを特徴とする。この様な状態を創出するためには、1)爪に定量的に感染源を接触させること、2)接触した感染源が爪に的確に固定されること、3)固定された感染源が的確に生育することの3つの条件が必要となる。1)のためには、分生子のみを取り出し、播種する分生子の数をコントロールすることにより、実現される。かかる分生子の数は、1×105〜1×109分生子/MLであることが好ましい。2)の条件としては、高湿度に設定し、爪に於ける水分量が十分であることが上げられる。この為には、爪周囲の湿度が90〜100%であることが好ましく、より好ましくは93〜98%であることが例示できる。又、かかる湿度の設定は、真菌の一部、特に好ましくは分生子を播種した部位から、反対側の面に緩やかな水蒸気の流れが生じるように、爪甲側と、爪床側で差が生じるように設定することが好ましい。この為には、分生子などの真菌乃至はその一部を播種した側を水などの水性担体を貯留させたチャンバーなどの密閉構造で密閉し、この系からの水蒸気が爪を通してのみ出入り出来るような状態を作っておくことが好ましい。この様なチャンバーとしては、経皮吸収などの検討に用いられるフランツセルを利用することが出来る。フランツセルの上面は開放系として、恒温恒湿機などに保存して、湿度をコントロールすることが好ましい。又、この様なチャンバーに爪を固定する場合には爪の上下に弾性材料で作成したO−リングを設置しチャンバー水性担体収納部の密閉生を高めることが好ましい。又、チャンバーに充填する水性担体は、塩などを加えて飽和素性気圧を調整することも出来る。前記水性担体と、採取された爪とは非接触状態に保たれる。この様な状態は後記に示す治具を用いることにより達成される。又、十分に爪内部にまで真菌が固着するためには、培養温度を低温にすることが好ましく、具体的には、温度が25〜30℃であることが好ましく、より好ましくは、26〜29℃であることがより好ましい。又、この温度条件で爪に一様に感染を広げるためには、7日間から14日間の長期間に亘って培養することが好ましく、8日間から12日間の培養がより好ましい。この様に温度を低温に、培養時間を長期間に設定することにより、菌体が、爪に対して均一に、一様な深度で、且つ、深部にまで菌糸を伸ばすようになるからである。斯くして得られた爪白癬モデルは、爪片全体に生存している真菌が一様な深度で広がっており、これに抗真菌剤を塗布し、真菌の生活状況を調べることにより、前記抗真菌剤の作用を鑑別することが出来る。通常、イン・ビトロで爪に均一な真菌感染を起こさせて爪白癬モデルを作成することは困難である。これは生体から切り離した爪が真菌にとって生育しやすい環境ではないことが大きな理由であると考えられる。特に生育に阻害的に働く環境条件としては水分が少ないことが挙げられる。   The onychomycosis model of the present invention uses a nail that has not been infected with a fungus collected from animals including humans, and propagates a fungus that uses the nail as a nutrient source to create a state of onychomycosis in vitro. It is characterized by that. In order to create such a state, 1) quantitatively contact the infection source with the nail, 2) the contacted infection source is accurately fixed to the nail, and 3) the fixed infection source is accurate. Three conditions for growth are required. For 1), only conidia are taken out and controlled by controlling the number of conidia seeded. The number of such conidia is preferably 1 × 10 5 to 1 × 10 9 conidia / ML. As the condition of 2), it is set that the humidity is set to a high humidity and that the amount of water in the nail is sufficient. For this purpose, the humidity around the nail is preferably 90 to 100%, more preferably 93 to 98%. In addition, the humidity setting is such that there is a difference between the nail plate side and the nail bed side so that a gentle flow of water vapor occurs on the opposite surface from the part of the fungus, particularly preferably the conidia seeded. It is preferable to set so as to occur. For this purpose, the side on which the fungus such as conidia or a part thereof is seeded is sealed with a sealed structure such as a chamber in which an aqueous carrier such as water is stored so that water vapor from this system can only enter and exit through the nail. It is preferable to create a simple state. As such a chamber, Franz cells used for studies such as percutaneous absorption can be used. The upper surface of the Franz cell is preferably an open system and stored in a thermo-hygrostat or the like to control the humidity. Moreover, when fixing a nail | claw to such a chamber, it is preferable to install the O-ring made from the elastic material on the upper and lower sides of a nail | claw, and to heighten the hermetic seal of a chamber aqueous carrier storage part. In addition, the aqueous carrier filled in the chamber can be adjusted to a saturated elementary pressure by adding salt or the like. The aqueous carrier and the collected nail are kept in a non-contact state. Such a state is achieved by using a jig described later. In addition, in order for fungi to sufficiently adhere to the inside of the nail, it is preferable to lower the culture temperature. Specifically, the temperature is preferably 25 to 30 ° C., more preferably 26 to 29. More preferably, it is ° C. In order to spread the infection uniformly on the nail under this temperature condition, the culture is preferably performed over a long period of 7 to 14 days, more preferably 8 to 12 days. This is because by setting the temperature to a low temperature and the culture time to a long period in this way, the fungus body extends the mycelium uniformly to the nail at a uniform depth and deep. . In the thus-obtained onychomycosis model, the fungus that is alive throughout the nail piece spreads at a uniform depth, and an antifungal agent is applied to the fungus to examine the living state of the fungus. The action of fungicides can be differentiated. Usually, it is difficult to create a nail ringworm model by causing a uniform fungal infection in the nail in vitro. This is probably because the nail cut from the living body is not easy for fungi to grow. In particular, the environmental conditions that inhibit growth are low moisture.

斯くして得られた爪白癬モデルにおける菌の生育状況はATPの産生量を指標に、ATP産生量が多い場合には、生存菌数が多く、産生量が少ない場合には生存菌数が少ないと判別することにより知ることが出来る。ATPの産生量は、爪を生検トレパンなどで打ち抜き、ブラック96穴プレートにおき、「マイクロバイアル・セル・バイラビリティ・アッセー(Microbial Cell viability Assay;BacTiter-Glo社製;以下ATP測定キットと称することもある)」を用いて測定することが出来る。   The growth status of the fungus in the onychomycosis model thus obtained is based on the amount of ATP produced, and when the amount of ATP produced is large, the number of viable bacteria is large, and when the amount of production is small, the number of viable bacteria is small. You can know by distinguishing. The amount of ATP produced was punched out with a biopsy trepan or the like and placed in a black 96-well plate, and the microbial cell viability assay (manufactured by BacTiter-Glo; hereinafter referred to as ATP measurement kit). Sometimes measured).

又、真菌の生育状況の確認には、ATP量以外にも、チミジン取込量等の他の対しゃん関連物質の収支を指標とした評価でも鑑別できるし、切片に切り出して染色し、組織学的な検討によっても鑑別できる。前記染色法としては、例えば、PAS染色、ニュートラルレッドによる染色などが好ましく例示できる。   In addition to confirming the growth of fungi, in addition to the amount of ATP, it can also be identified by evaluation using the balance of other anti-sham substances such as the amount of thymidine incorporation, and cut into sections and stained, It can also be differentiated by scientific examination. Preferred examples of the staining method include PAS staining and neutral red staining.

斯くして得られた、本発明の爪白癬モデルは均一な深度で均一に真菌が爪に浸潤している特徴を有し、その感染再現性の良いことから爪用抗真菌剤の評価などに用いることが出来る。爪用抗真菌剤の評価は、前記のチャンバーに固定された状態の爪白癬モデルを使用して行う。チャンバーにおいて開放系に配向した爪甲を生理食塩水などで拭いて清浄にし、これに被験体を塗布する。塗布は1〜5回/1日、より好ましくは1〜2回/日行うことが好ましく、塗布に先立って、爪甲部を予め拭き取って清浄に保つことが好ましい。この操作は5〜30日行うことにより、爪の真菌の生育を抑制する作用の強さを鑑別することが出来る。生育の抑制はATP産生量のコントロールに比した抑制率として把握することが出来る。   The thus-obtained onychomycosis model of the present invention has the feature that fungi are uniformly infiltrated into the nail at a uniform depth, and its infection reproducibility is good for evaluating antifungal agents for nail, etc. Can be used. The antifungal agent for nail is evaluated using a nail ringworm model fixed in the chamber. The nail plate oriented in an open system in the chamber is cleaned by wiping with physiological saline or the like, and the subject is applied thereto. Application is preferably performed 1 to 5 times / day, more preferably 1 to 2 times / day, and prior to application, it is preferable to wipe the nail plate portion in advance to keep it clean. By performing this operation for 5 to 30 days, it is possible to distinguish the strength of the action of suppressing the growth of the nail fungus. The inhibition of growth can be grasped as the inhibition rate compared to the control of ATP production.

かかる評価は、製剤成分と有効成分との組み合わせ効果を鑑別することにも応用することが出来る。即ち、製剤特性まで含めた抗真菌剤の評価を行うことが出来る。   Such evaluation can also be applied to discriminate the combination effect of the formulation component and the active ingredient. That is, it is possible to evaluate antifungal agents including pharmaceutical properties.

以下に、実施例を挙げて、更に詳細に本発明について説明を加える。   Hereinafter, the present invention will be described in more detail with reference to examples.

ボランティアより提供されたヒト爪サンプルの中から以下に示す爪の選定基準に合うものを選定した。入手後の爪サンプルは通し番号を付与し,マイクロメーターで厚さを測定した。   The human nail samples provided by volunteers were selected to meet the following nail selection criteria. The obtained nail samples were given serial numbers and the thickness was measured with a micrometer.

<爪の選定基準>
1.爪に著しく着色のないもの,目立つ汚れのないものであること。
2.爪が極端に湾曲していないものであること。
3.長さが5mm以上あり,5mm×5mmが2箇所取れるサイズのものであること。
4.ひび割れや亀裂のないもの、欠けていないものであること。
5.極端に厚かったり薄かったりしないものであること。
<Nail selection criteria>
1. The nail must not be markedly colored or noticeable.
2. The nails are not extremely curved.
3. The length must be 5 mm or more, and the size must be 2 mm × 5 mm.
4). There should be no cracks or cracks, and no cracks.
5. It must not be extremely thick or thin.

以下の手順に従って、感染のための分生子分散液を作成した。
28℃に設定したテーハー式デジタル孵卵器で培養されているFSDA培地上のトリコフィトン・メンタグロファイテス(TIMM1189株)について,菌糸および分生子の十分な発育を確認した。50mLチューブに0.05%Tween(登録商標)80含有生理食塩液を適量とり、FSDA培地表面に発育した菌糸および分生子を白金耳で擦り,チューブに入れて分生子を浮遊させた。その後、よくピペッティングして均一な懸濁液にし,セルストレーナーでろ過して菌糸を除去したのち分生子濃度を算出し、最終的に1.0×104conidia(分生子)/mLとなるように調整した。
A conidia dispersion for infection was made according to the following procedure.
For Trichophyton mentagrophytes (TIMM1189 strain) on FSDA medium cultured in a Tacher digital incubator set at 28 ° C, sufficient growth of hyphae and conidia was confirmed. An appropriate amount of physiological saline containing 0.05% Tween (registered trademark) 80 was taken into a 50 mL tube, and the mycelium and conidia grown on the surface of the FSDA medium were rubbed with platinum ears and placed in a tube to float the conidia. Then pipette well to make a uniform suspension, filter with a cell strainer to remove mycelia, calculate the conidia concentration, and finally adjust to 1.0 × 104conidia (conidia) / mL .

ボランティアから提供された爪を水とエタノールで清浄に処置し、図1に示す手順でフランツセルにセットし、これを湿度95%、28℃のインキュベーターで培養した、即ち、つめを中央で2分割し、上下にO−リングをセットし、中央に直径2mmの円形の窓を有するポリテトラフルオロエチレン製の板2枚を用いて上下で窓部を爪が塞ぐ形で固定した。爪床部を上面に向け、分生子分散液(1×104分生子/mL)を10μL爪床部に滴下した。上下をひっくり返し、爪床部が下面になるようにレシーバー部に蒸留水を充填したフランツセルにセットした。この時、蒸留水とセットした爪床部とが接触しないように注意した。これを湿度95%、28℃のインキュベーターで9日間培養した。このものを生検トレパンで打ち抜き、マイクロプレートに置き、これに注射用蒸留水130μLを加え、ATP測定キット混液130μLを更に加え、プレートミキサーで混合し、添加5分後に蛍光分析を行った。検量線を引くために、ATPの標準液(1×10-7〜1×10-11mol/L )を用意し、これも同時に測定した。標準液の発光値から検量線を引き、サンプル中のATP量を定量した。尚、爪の感染状況は感染7日目の状況を図2に示す。一様に、均一な深度で感染していることが判る。   The nail provided by the volunteer was cleanly treated with water and ethanol, set in a Franz cell according to the procedure shown in Fig. 1, and cultured in an incubator at 95% humidity and 28 ° C. Then, O-rings were set on the top and bottom, and two plates made of polytetrafluoroethylene having a circular window with a diameter of 2 mm at the center were used to fix the nails closed at the top and bottom. With the nail bed facing the upper surface, 10 μL of the conidia dispersion (1 × 10 4 conidia / mL) was dropped onto the nail bed. The receiver part was set in a Franz cell filled with distilled water so that the nail bed part was on the bottom. At this time, care was taken not to contact the nail bed set with distilled water. This was cultured in an incubator at 95% humidity and 28 ° C. for 9 days. This was punched out with a biopsy trepan, placed on a microplate, 130 μL of distilled water for injection was added thereto, 130 μL of an ATP measurement kit mixed solution was further added, mixed with a plate mixer, and fluorescence analysis was performed 5 minutes after the addition. In order to draw a calibration curve, an ATP standard solution (1 × 10 −7 to 1 × 10 −11 mol / L) was prepared, and this was also measured at the same time. A calibration curve was drawn from the luminescence value of the standard solution to quantify the amount of ATP in the sample. In addition, the infection state of the nail is shown in FIG. It can be seen that the infection is uniformly and at a uniform depth.

Figure 0005458368
Figure 0005458368

本発明は、抗真菌医薬の評価に応用することが出来る。   The present invention can be applied to the evaluation of antifungal drugs.

本発明の評価法で使用するチャンバーの構造示す図である。It is a figure which shows the structure of the chamber used with the evaluation method of this invention. 本発明の爪白癬モデルの感染状況を示す図である。(図面代用写真)It is a figure which shows the infection condition of the onychomycosis model of this invention. (Drawing substitute photo)

Claims (4)

爪全体が均一な深度で感染した爪白癬モデルであって、ヒトを含む動物より採取した非感染爪の爪床側に、予め培養して定量可能な状態に調整した、真菌乃至は分生子の分散液を播種し、水性担体と接することなく、温度25〜30℃、湿度90〜100%の範囲にて、7〜14日間、且つ、爪甲側よりも爪床側の湿度が高い状態で培養することを特徴とする、爪白癬モデルの製造法。 A model of onychomycosis in which the entire nail is infected at a uniform depth, and the fungus or conidia of the non-infected nail collected from an animal including humans is cultivated in advance and adjusted to a quantifiable state . Seeding the dispersion, without contact with the aqueous carrier, at a temperature of 25 to 30 ° C. and a humidity of 90 to 100%, for 7 to 14 days and in a state where the humidity on the nail bed side is higher than the nail plate side A method for producing an onychomycosis model, characterized by culturing. 請求項1に記載の爪白癬モデルの製造方法で製造されたモデルの爪甲側に抗真菌剤を投与し、爪中の真菌の状態をATP産生量を指標に、ATP産生量が大きいときには、生存真菌の量が多く、ATP産生量が低いときには、生存真菌の量が少ないと判別し、投与により生存菌数が減じる程度が高い薬剤ほど抗真菌効果の高い薬剤であると鑑別することを特徴とする、抗真菌薬剤の効果の鑑別法。 When an antifungal agent is administered to the nail plate side of the model produced by the method for producing an onychomycosis model according to claim 1 , and when the ATP production amount is large using the ATP production amount as an indicator of the state of the fungus in the nail, When the amount of viable fungus is large and the amount of ATP produced is low, it is determined that the amount of viable fungus is small, and a drug whose degree of viable bacteria is reduced by administration is identified as a drug having a higher antifungal effect. And a method for differentiating the effects of antifungal agents. 請求項1に記載の爪白癬モデルの製造方法において、温度25〜30℃、湿度90〜100%の範囲にて、7〜14日間、且つ、爪甲側よりも爪床側の湿度を高く保つための治具であって、爪の水分非透過性に依存して密閉すべき構造を構築する、爪よりも小さい窓部を有する2枚のアタッチメントとアタッチメントと爪で密閉されるべき空間を有する、水性担体保持可能なチャンバーとを構成要件とする爪白癬モデル作成用の治具。 In the manufacturing method of the onychomycosis model according to claim 1 , the humidity on the nail bed side is kept higher than the nail plate side for 7 to 14 days at a temperature of 25 to 30 ° C and a humidity of 90 to 100%. A jig for forming a structure to be sealed depending on the moisture impermeability of the nail, having two attachments having a window portion smaller than the nail, a space to be sealed with the attachment, and the nail A jig for creating a nail ringworm model comprising a chamber capable of holding an aqueous carrier. 前記治具は、爪とアタッチメントとの接触部の間に弾性緩衝体を有することを特徴とする、請求項記載の治具。The jig according to claim 3 , wherein the jig has an elastic buffer between contact portions between the claw and the attachment.
JP2008321700A 2008-12-18 2008-12-18 Manufacturing method of onychomycosis model Active JP5458368B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2008321700A JP5458368B2 (en) 2008-12-18 2008-12-18 Manufacturing method of onychomycosis model

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008321700A JP5458368B2 (en) 2008-12-18 2008-12-18 Manufacturing method of onychomycosis model

Publications (2)

Publication Number Publication Date
JP2010142149A JP2010142149A (en) 2010-07-01
JP5458368B2 true JP5458368B2 (en) 2014-04-02

Family

ID=42563244

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008321700A Active JP5458368B2 (en) 2008-12-18 2008-12-18 Manufacturing method of onychomycosis model

Country Status (1)

Country Link
JP (1) JP5458368B2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010142164A (en) * 2008-12-19 2010-07-01 Pola Pharma Inc Method for producing nail trichophytic model
GB0922403D0 (en) * 2009-12-22 2010-02-03 Novabiotics Ltd Method

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001133449A (en) * 1999-11-02 2001-05-18 Pola Chem Ind Inc Method for evaluating antifungal agent for nail
EP1627610A1 (en) * 2004-08-21 2006-02-22 TLT Medical Ltd Drug delivery throug application in nails
JP4452704B2 (en) * 2005-08-31 2010-04-21 株式会社ポーラファルマ A method for differentiating the effectiveness of antifungal agents
JP4824493B2 (en) * 2005-08-31 2011-11-30 株式会社ポーラファルマ Antifungal evaluation method
EP1971324A1 (en) * 2006-01-02 2008-09-24 TLT Medical Ltd Pharmaceutical composition for the treatment of nail diseases
RU2419429C2 (en) * 2006-03-08 2011-05-27 Нихон Нохияку Ко.,Лтд. Pharmaceutical composition for external application
WO2007102243A1 (en) * 2006-03-08 2007-09-13 Nihon Nohyaku Co., Ltd. External pharmaceutical composition

Also Published As

Publication number Publication date
JP2010142149A (en) 2010-07-01

Similar Documents

Publication Publication Date Title
Truman et al. Viable M. leprae as a research reagent
JP6153731B2 (en) Bacteria measurement method, antibacterial and / or bacteria reduction evaluation method, and holding material
CN102414324B (en) Rapid sterility microassay
Gadd Toxicity screening using fungi and yeasts
Abdulkhair et al. Plant pathogens
Gent et al. Susceptibility of hop crown buds to powdery mildew and its relation to perennation of Podosphaera macularis
JP5458368B2 (en) Manufacturing method of onychomycosis model
JP6452853B2 (en) Thin film culture device with carbon dioxide generator
CN103756913B (en) A kind of rose dark brown Isaria bacterial strain
CN101571532A (en) Novel method for measuring biological activity of biological pesticides
JP2019530455A (en) Biological antifungal liquid product containing microbial Psium origolandrum and method of manufacture
JP2010142164A (en) Method for producing nail trichophytic model
Anith Mature coconut as a bio-fermentor for multiplication of plant growth promoting rhizobacteria
CN1687774A (en) Method for measuring virulence of bactericide to bacterium of downy mildew of cucumber
ÖZKANLAR et al. Mycozoonosis associated with ringworm of calves in Erzurum Province, Turkey
JP2007093584A (en) Differentiation method for validity of antifungal agent
CN109463402A (en) A kind of preparation method and application of cinnamomum camphora essential oil quorum-quenching agent
RU2737149C1 (en) Method for long-term storage of leprosy mycobacteria
JP5250561B2 (en) Animal infection model of microbial infection
Trkulja et al. The most common diseases of ornamental plants in the entity of Republic of SRPSKA (Bosnia and Herzegovina).
CN1683515A (en) Globisporal beauveria bassiana
RU2413764C1 (en) Dense nutrient medium for cultivation of mycobacteria, isolated from lepromas of leprosy patients
RU2281507C2 (en) Method for evaluating toxicity of bacterial antigens
Schoemaker Infectious diseases in rabbits: diagnosis, treatment and control
RU2403282C1 (en) Liquid culture medium for culturing mycobacteria from leproma from leprosy patients

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110617

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130801

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131224

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131225

R150 Certificate of patent or registration of utility model

Ref document number: 5458368

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R371 Transfer withdrawn

Free format text: JAPANESE INTERMEDIATE CODE: R371

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250